William Walsh

7.3k total citations · 2 hit papers
41 papers, 4.6k citations indexed

About

William Walsh is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Hematology. According to data from OpenAlex, William Walsh has authored 41 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 19 papers in Pulmonary and Respiratory Medicine and 8 papers in Hematology. Recurrent topics in William Walsh's work include Lung Cancer Treatments and Mutations (11 papers), Lung Cancer Diagnosis and Treatment (7 papers) and Immunotherapy and Immune Responses (5 papers). William Walsh is often cited by papers focused on Lung Cancer Treatments and Mutations (11 papers), Lung Cancer Diagnosis and Treatment (7 papers) and Immunotherapy and Immune Responses (5 papers). William Walsh collaborates with scholars based in United States, Germany and Canada. William Walsh's co-authors include Beverly Plunkett, Steven J. Kuerbitz, Michael B. Kastan, Albert J. Fornace, Tyler Jacks, B Vogelstein, Wafik S. El‐Deiry, France Carrier, Khaled El‐Shami and Aaron D. Schimmer and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and Journal of Clinical Oncology.

In The Last Decade

William Walsh

38 papers receiving 4.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia

1992 2.7k citations Wafik S. El‐Deiry, France Carrier et al. Cell profile →
Wild-type p53 is a cell cycle checkpoint determinant following irradiation.

1992 1.6k citations Beverly Plunkett, William Walsh et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
William Walsh United States	10	3.3k	3.2k	906	877	374	41	4.6k
David C. Olson United States	13	3.4k 1.0×	3.5k 1.1×	717 0.8×	965 1.1×	341 0.9×	20	4.9k
Ruth Maya Israel	12	4.6k 1.4×	4.0k 1.2×	965 1.1×	880 1.0×	630 1.7×	13	5.7k
Claude Caron de Fromentel France	27	2.3k 0.7×	2.5k 0.8×	924 1.0×	578 0.7×	205 0.5×	49	3.8k
Daniele Bergamaschi United Kingdom	23	2.1k 0.6×	1.6k 0.5×	593 0.7×	496 0.6×	305 0.8×	42	3.1k
Giulia Fontemaggi Italy	33	2.8k 0.9×	1.6k 0.5×	1.2k 1.3×	423 0.5×	438 1.2×	58	3.7k
Gareth L. Bond United Kingdom	23	2.6k 0.8×	2.2k 0.7×	825 0.9×	232 0.3×	278 0.7×	41	3.6k
Shunsuke Kato Japan	27	2.5k 0.7×	2.6k 0.8×	1.2k 1.3×	311 0.4×	212 0.6×	102	4.4k
Aart G. Jochemsen Netherlands	26	3.0k 0.9×	3.0k 0.9×	545 0.6×	658 0.8×	365 1.0×	37	3.7k
Carl G. Maki United States	27	2.3k 0.7×	1.8k 0.6×	584 0.6×	400 0.5×	328 0.9×	62	2.9k
Ante S. Lundberg United States	17	3.0k 0.9×	1.7k 0.5×	545 0.6×	381 0.4×	558 1.5×	39	4.7k

Countries citing papers authored by William Walsh

Since Specialization

Citations

This map shows the geographic impact of William Walsh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William Walsh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William Walsh more than expected).

Fields of papers citing papers by William Walsh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William Walsh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William Walsh. The network helps show where William Walsh may publish in the future.

Co-authorship network of co-authors of William Walsh

This figure shows the co-authorship network connecting the top 25 collaborators of William Walsh. A scholar is included among the top collaborators of William Walsh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William Walsh. William Walsh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kennedy, Alice, William Walsh, Shyam A. Patel, et al.. (2023). Telehealth through the pandemic at a safety net hospital: observations and next steps for cancer care delivery. Frontiers in Public Health. 11. 1186350–1186350. 1 indexed citations

McIntosh, Lacey, Max P. Rosen, Kriti Mittal, et al.. (2021). Coordination and optimization of FDG PET/CT and COVID-19 vaccination; Lessons learned in the early stages of mass vaccination. Cancer Treatment Reviews. 98. 102220–102220. 12 indexed citations

Ray, Meredith, Nicholas R. Faris, Matthew Smeltzer, et al.. (2021). Survival Impact of an Enhanced Multidisciplinary Thoracic Oncology Conference in a Regional Community Health Care System. JTO Clinical and Research Reports. 2(8). 100203–100203. 9 indexed citations

Varlotto, John M., Malcolm M. DeCamp, Paul Rava, et al.. (2020). The rates of second lung cancers and the survival of surgically-resected second primary lung cancers in patients undergoing resection of an initial primary lung cancer. Lung Cancer. 147. 115–122. 7 indexed citations

Varlotto, John M., Isabel Cristina Martins Emmerick, M Decamp, et al.. (2020). The Incidence of Node-Positive Non-small-Cell Lung Cancer Undergoing Sublobar Resection and the Role of Radiation in Its Management. Frontiers in Oncology. 10. 417–417. 1 indexed citations

Osarogiagbon, Raymond U., Nicholas R. Faris, Matthew Smeltzer, et al.. (2020). Survival impact of multidisciplinary thoracic oncology care in a regional healthcare system.. Journal of Clinical Oncology. 38(15_suppl). 2004–2004. 1 indexed citations

Varlotto, John M., John C. Flíckinger, Malcolm M. DeCamp, et al.. (2018). Population‐based differences in the outcome and presentation of lung cancer patients based upon racial, histologic, and economic factors in all lung patients and those with metastatic disease. Cancer Medicine. 7(4). 1211–1220. 23 indexed citations

Migdady, Yazan, Yiqin Xiong, Karen Dresser, et al.. (2018). Immunohistochemical expression and prognostic value of PD-L1 in Extrapulmonary small cell carcinoma: a single institution experience. Journal for ImmunoTherapy of Cancer. 6(1). 42–42. 16 indexed citations

Saini, Neeraj, et al.. (2018). Rare gene fusion rearrangement SPTNB1-PDGFRB in an atypical myeloproliferative neoplasm. Molecular Cytogenetics. 11(1). 56–56. 2 indexed citations

10.

Varlotto, John M., John C. Flíckinger, Malcolm M. DeCamp, et al.. (2018). The Role of Race and Economic Characteristics in the Presentation and Survival of Patients With Surgically Resected Non-Small Cell Lung Cancer. Frontiers in Oncology. 8. 146–146. 8 indexed citations

11.

Li, Tianhong, Bilal Piperdi, William Walsh, et al.. (2016). Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non–small-cell Lung Cancer. Clinical Lung Cancer. 18(1). 60–67. 6 indexed citations

12.

Nakabayashi, Mari, Wanling Xie, Geoffrey Buckle, et al.. (2013). Long-term Follow-up of a Phase II Trial of Chemotherapy Plus Hormone Therapy for Biochemical Relapse After Definitive Local Therapy for Prostate Cancer. Urology. 81(3). 611–616. 9 indexed citations

13.

Piperdi, Bilal, William Walsh, Zheng Zhou, et al.. (2012). Phase-I/II Study of Bortezomib in Combination with Carboplatin and Bevacizumab as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology. 7(6). 1032–1040. 28 indexed citations

14.

Parikh, Sameer A., Hagop M. Kantarjian, Aaron D. Schimmer, et al.. (2010). Phase II Study of Obatoclax Mesylate (GX15-070), a Small-Molecule BCL-2 Family Antagonist, for Patients With Myelofibrosis. Clinical Lymphoma Myeloma & Leukemia. 10(4). 285–289. 69 indexed citations

15.

Anwar, Khurshid, et al.. (2008). To compare the results of Adjuvant Online and Oncotype DX in estimating risk for relapse in hormone receptor positive stage I breast cancer patients. Journal of Clinical Oncology. 26(15_suppl). 22069–22069. 1 indexed citations

16.

Przepiorka, Donna, et al.. (2007). Myelodysplastic syndrome after autologous peripheral blood stem cell transplantation for multiple myeloma. Bone Marrow Transplantation. 40(8). 759–764. 14 indexed citations

17.

Seidler, C. W., et al.. (2006). Phase I-II trial of daily thalidomide in combination with docetaxel in patients with relapsed non-small cell lung cancer: A final analysis. Journal of Clinical Oncology. 24(18_suppl). 17060–17060. 1 indexed citations

18.

Becker, Pamela S., Adrianne N. Hanks, William Walsh, et al.. (2005). In Vivo Chemotherapy Protection and Efficacy of Multidrug Resistance (MDR-1) Gene Transfer in a Patient with Refractory Non-Hodgkin’s Lymphoma (NHL).. Blood. 106(11). 3054–3054. 1 indexed citations

19.

Issa, Rami, et al.. (2004). Esophagectomy in a patient with Aids. Diseases of the Esophagus. 17(3). 270–272. 7 indexed citations

20.

El‐Deiry, Wafik S., France Carrier, Tyler Jacks, et al.. (1992). A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell. 71(4). 587–597. 2660 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact